C&R Research Inc. 359090
KRX · South Korea · Finance
KRW 2,295.00-70.00 (-2.96%)
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
C&R Research will deploy Taimei Technology’s digital platforms and AI agents across several clinical trial projects.
Taimei Technology (HK.02576), a leading AI-powered drug clinical development platform company, and C&R Research (A359090), a top-tier CRO in South Korea, signed an enterprise-level strategic partnership agreement, officially launching the development of an AI-based clinical trial operations system.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.